An innovative urinary drainage system that could reduce NHS CAUTI treatment costs by 10% and increase quality-of-life for men suffering from chronic incontinence

Ingenion是一家总部位于英国的医疗设备中小企业，其核心项目团队由Edward Cappabianca（项目负责人）、Susan Finch（项目经理）、James Barnett（设计工程师）、Tim Maloney（商务总监）和Zia Mursaleen（财务经理）组成。尿失禁影响身体和心理健康，造成羞辱和社会问题。频繁的导尿会增加导尿相关尿路感染（CAUTIs）的风险，这可能是致命的，NHS每年要花费5.676亿英镑。CAUTIs占所有医疗保健相关感染（HCAIs）的17.2%，据估计，HCAIs每年花费NHS 16 - 50亿英镑（加拿大感染控制杂志，2020年9月）。长期导管使用者平均每年经历2.7次CAUTIs（康乐保，2023年），每次事件的成本为3500英镑。英国约有9万人使用长期导尿管，全球每年使用的导尿管超过40万根。有些人试图通过少喝水来控制尿失禁，但这已经被证明会使一些看似无关的疾病恶化，比如痴呆症。为了解决这一未满足的需求，Ingenion正在开发一种革命性的留置泌尿引流系统（_**cym**active_ SealSoft），消除了对外部袋子或管道的需要。**cym** active_sealsoft尿失禁装置将为男性患者提供正常的填充/排空周期，没有任何不便或CAUTIs的风险。这项创新将对患有多发性硬化症、帕金森氏症、脊髓损伤和脊柱裂的患者产生重大影响。这不仅会提高他们的生活质量，而且还会通过让他们保持活跃来帮助延长他们的预期寿命。该设备的独特卖点是其防泄漏设计和专利的电磁阀技术，这确保了更大的信心和潜在的经济效益，NHS减少了10%的CAUTI治疗费用，与CAUTIs相关的hcai每年可达5700万英镑。

Ingenion is a UK-based medical device SME with a core project team of Edward Cappabianca (project lead), Susan Finch (project manager), James Barnett (design engineer), Tim Maloney (commercial director) and Zia Mursaleen (finance manager).Urinary incontinence impacts physical and emotional health, causing humiliation and social issues. Frequent catheterisation increases the risk of catheter-associated urinary tract infections (CAUTIs), which can be fatal and cost the NHS £567.6M/year. CAUTIs represent 17.2% of all Health-Care Associated Infections (HCAIs), and HCAIs have been estimated to cost the NHS between £1.6-£5B/year (Canadian-Journal-of -Infection-Control,Sep2020). Long-term catheter users experience an average of 2.7 CAUTIs per year (Coloplast, 2023), with a cost of £3,500 per incident. Around 90,000 people in the UK live with long-term catheters, with over 4B catheters used worldwide annually. Some people try to manage incontinence by drinking less water, but this has been shown to worsen apparently unrelated conditions, such as dementia.To solve this unmet need, Ingenion is developing a revolutionary indwelling urinary drainage system (_**cym**active_ SealSoft) that eliminates the need for external bags or tubes. The _**cym**active_ SealSoft device for incontinence will provide male patients with normal fill/void cycles without any inconvenience or risk of CAUTIs.This innovation will have a significant impact on patients suffering from MS, Parkinson's, spinal cord injuries and spina bifida. Not only will it improve their quality of life, but it will also help increase their life expectancy by allowing them to remain active. The unique selling points of this device are its leak-proof design and patented magnetic valve technology, which ensures greater confidence and a potential economic benefit from a reduction in CAUTI treatment costs for the NHS by 10% of the HCAIs related to CAUTIs could be as much as £57M/year.